Glonghui, December 13|Some investors asked Saisheng Pharmaceutical (300485.SZ) on the investor interactive platform, “There are many patients with respiratory infections and influenza viruses every winter. Has the company increased production of anti-virus drugs and anti-allergic antidotes? Is there room for the company to improve cardiovascular, diabetes and other products in the future?” The company replied that the company will arrange production plans reasonably according to the order situation. On the basis of the original product structure, the company combines the company's existing resource conditions to carry out in-depth research on polypeptide biomedicine, new biomaterials, and diagnosis, treatment and management of chronic diseases, making full use of the favorable policy environment of the country to support the development of the biomedical industry, and strives to achieve the company's continuous, stable and healthy development. Currently, the company's research projects involving cardiovascular/cardiovascular, and cerebrovascular projects include GGE3, JTYM, etc., which are in the pre-clinical research stage; the subsidiary Saierbiao's research projects involving diabetes are dagliflozin metformin sustained-release tablets, and the subsidiary Junyuan Pharmaceutical has an approval number for metformin hydrochloride tablets.